1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth

[1]  信澤 純人.  Molecular classification of low-grade diffuse gliomas , 2012 .

[2]  A. von Deimling,et al.  Glioma IDH1 mutation patterns off the beaten track. , 2011, Neuropathology and applied neurobiology.

[3]  Bin Wang,et al.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.

[4]  O. Chinot,et al.  Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis , 2010, Acta Neuropathologica.

[5]  R. Guillevin,et al.  IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas , 2010, Neurology.

[6]  K. Hoang-Xuan,et al.  All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2 , 2010, Neurology.

[7]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[8]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[9]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[10]  M. J. van den Bent,et al.  IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide , 2009, Neurology.

[11]  K. Hoang-Xuan,et al.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Christian Mawrin,et al.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.

[13]  P. Kleihues,et al.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. , 2009, The American journal of pathology.

[14]  J. Uhm.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2009 .

[15]  Frank M. Sacks,et al.  IDH 1 and IDH 2 Mutations in Gliomas , 2009 .

[16]  Luc Taillandier,et al.  Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection , 2009, Neurosurgical Review.

[17]  Andrey Korshunov,et al.  Analysis of the IDH1 codon 132 mutation in brain tumors , 2008, Acta Neuropathologica.

[18]  M. Rosenblum,et al.  Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas , 2008, Journal of Neuro-Oncology.

[19]  Susan M. Chang,et al.  Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Laurent Capelle,et al.  Dynamic history of low‐grade gliomas before and after temozolomide treatment , 2007, Annals of neurology.

[21]  Y. Marie,et al.  Prognostic stratification of patients with anaplastic gliomas according to genetic profile , 2006, Cancer.

[22]  E. Shaw,et al.  A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. , 2006, Cancer research.

[23]  L. Mariani,et al.  Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Luc Taillandier,et al.  Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas , 2006, Annals of neurology.

[25]  K. Hoang-Xuan,et al.  Chromosome 1p loss: A favorable prognostic factor in low‐grade gliomas , 2005, Annals of neurology.

[26]  Laurent Capelle,et al.  Continuous growth of mean tumor diameter in a subset of grade II gliomas , 2003, Annals of neurology.

[27]  M. J. van den Bent,et al.  Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features , 2003, Cancer.

[28]  P. Kleihues,et al.  Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[30]  J. Witjes,et al.  Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[31]  P. Kleihues,et al.  p53 protein accumulation and gene mutations in human glioma cell lines , 1993, International journal of cancer.

[32]  D. Louis,et al.  Comparative Study of p53 Gene and Protein Alterations in Human Astrocytic Tumors , 1993, Journal of neuropathology and experimental neurology.

[33]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[34]  P. J. Huber.  Robust Regression: Asymptotics, Conjectures and Monte Carlo , 1973 .

[35]  M. Kendall.  Statistical Methods for Research Workers , 1937, Nature.

[36]  Frank Yates,et al.  The Analysis of Multiple Classifications with Unequal Numbers in the Different Classes , 1934 .

[37]  Frank Yates,et al.  The principles of orthogonality and confounding in replicated experiments. (With Seven Text-figures.) , 1933, The Journal of Agricultural Science.